Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The FUDster very well knows that. It's just his job to accentuate the negative and twist info into a FUD narrative.
Hey FUDster, I conditioned my response as "pragmatically optimistic". You should've conditioned your post as "extreme pessimism".
So obvious your intentions that you don't mention the 150-day process, until I posted it.
Leave it to a FUDster to spin it as negatively as possible.
Hey a-hole, do you know anything about the EMA's accelerated assessment process?
Of course, a FUDster wouldn't want to post anything about the following process for accelerated assessment, would they?
https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-scientific-application-and-practical-arrangements-necessary-implement-procedure-accelerated-assessment-pursuant-article-149-regulation-ec-no-7262004_en.pdf
I'm presuming the LOI was submitted several months ago... prior to when the EMA reviewed the data and made their MAA recommendation. It's why Missling stated they will submit the MAA as early as possible in 2024.
We can always count on you for the FUD spin.
The "clock stops" aren't automatic; they're if needed.
If the MAA can be submitted by end of March, then under the special 150-day review process, we could see EMA approval for AD by August. That's the pragmatically optimistic viewpoint. It's also likely that an NDA will be filed for AD, and possibly Rett, in that timeframe. Then there's AU and UK, too.
There you go again, FUDster. Just so you know... $10 is were bas sold a large position in anticipation of the organized Rett TLR short attack that you signaled last year, with your "expecting cherry picked results" post. Thanks for that! Sub $6 is where bas reloaded. Now waiting for MAA, followed by MA and commercialization.
You do love to spin false narratives, don't you.
An NDA/MAA filing is 100k pages or more. It takes time to compile it all correctly.
I expect it'll happen this quarter.
Well, if investors won't sell, then the crooks have to run the stop-loss orders to get shares. They have a ton to cover before approval!
Which shorts want to be the last to cover?
The approval clock is ticking!
The collusive cabal (MMs/HFs) know this is their last opportunity to attack the price prior to approval... from where they'll have to start covering their collusive short position. It's always darkest before the dawn... and the corrupt manipulators never fail to make it so. Time to buy!
Your FUD attempts are quite weak. It's hard to believe that someone actually pays you for them.
Perhaps more FUD training might help. Call AF.
Why do you only appear when your handlers start taking the price down?
Is it a FUD alarm that you respond to? Oh, time to post FUD!
I guess we don't know if the LOI was submitted months ago.
Good post. Also, it's important to capture, both, cognitive and functional improvements... which the trial did with ADAS-Cog and CDR-SB... even if the mean score comparison for the subjective ADCS-ADL measurement wasn't quite stat. sig. in the short 48-wk trial... the CDR-SB score was.
Then consider the two ORs as supplemental data highlighting the strong responders for both cognition and function.
What?
Another for the 👺 list...
Most know that the manipulators want to make it the "darkest before the dawn" (before approval). Thus, this fabricated downward pressure is merely an opportunity to reload and/or buy more... before the dawn. Those 20M shorts will have to start covering sometime in the coming months... and a surprise partnership announcement would certainly cause quite a short squeeze.
I doubt your handlers would approve.
His only awareness is to try to impress his handlers.
I guess that would leave you exposed...
It's obvious that you're trying harder... 👺
No one can take your most-voted title away. 🤡
FUDsters 👺 out in force today to try to spook retail holders into selling, as we retest support, so that their handlers (collusive HFs/MMs) can begin their short covering. They have 20M collusive short shares that they'll have to cover over the next several months.
I should move you up higher in the 👺 list.
Yes, very much looking forward to the peer-reviewed journal, MAA submission and approval this year!
Those were the company's words.
Did you notice that blarcamesine is 2.5x better than trofinetide, with a much better safety profile? Less seizures as well. Of course you noticed it, but it doesn't fit with your FUD narratives.
Let's see... update website or work on MAA package? Which one is most important to shareholders?
Gee, any other insignificant items you can think of? LIke Missling's hair appt?
We already know the answer to that... in how extraordinary the Rett placebo scores were, that unfortunately skewed the results. They were 4x better than the placebo arm in the trofinetide trial. Most unbelievable. But we also saw that blarcamesine performed 2.5x better than trofinetide. Most impressive.
Because of this extraordinary placebo "performance", the results weren't technically stat. sig. (though close), but QoL improvements and seizure reductions, as well as being a very safe drug, make it a successful trial. I'm confident that the RAs will also see it this way.
But we were talking about the AD P2b/3 trial that MET ALL ENDPOINTS.
ALL endpoints WERE met, as stated by the company... thus, it WAS very successful.
Are you really trying to play that losing hand again?
FUDster continues to ignore the Odds Ratios (included in SAP) that clearly showed meaningful IMPROVEMENTS over baseline for both ADAS-Cog and ADCS-ADL. Where >3x of treated patients IMPROVED stat.sig. compared to placebo. Thus, ALL ENDPOINTS MET!
I've seen before, with other biotechs, how the collusive AF cabal, with their paid FUDsters, will even short attack a peer-reviewed journal publication with more made-up lies of "cherry picked data", "moved goalposts", even "paid docs/reviewers". Their nonsense is so ridiculous and pathetic.
The BS should stop once approval is granted, but we know they'll still attack Missling with their bullschitt narratives.
Unfortunately, he's not...
What a bunch of nonsense! Your typical 👺 post.